Rogers Corp (ROG)

102.94
NYSE : Technology
Prev Close 102.58
Day Low/High 102.84 / 106.20
52 Wk Low/High 51.98 / 106.20
Avg Volume 128.70K
Exchange NYSE
Shares Outstanding 18.09M
Market Cap 1.86B
EPS 2.70
P/E Ratio 38.71
Div & Yield N.A. (N.A)

Latest News

Rogers Corporation Reports First Quarter 2017 Results

Rogers Corporation Reports First Quarter 2017 Results

Rogers Corporation (NYSE:ROG) today announced financial results for the 2017 first quarter.

New Data At AAN Reinforce Clinical Benefit Of Genentech's OCREVUS (Ocrelizumab) For Relapsing And Primary Progressive Multiple Sclerosis

New Data At AAN Reinforce Clinical Benefit Of Genentech's OCREVUS (Ocrelizumab) For Relapsing And Primary Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from the OCREVUS™ (ocrelizumab) clinical trial programs will be presented during the 69th American Academy of...

Rogers Schedules First Quarter 2017 Earnings Call For April 27

Rogers Schedules First Quarter 2017 Earnings Call For April 27

Rogers Corporation (NYSE:ROG) plans to announce first quarter 2017 results on April 26 after market close, which will be followed by a conference call on April 27 at 9am ET.

Roche Diagnostics Recognizes Sentara Consolidated Laboratories As Roche Molecular Center Of Excellence

Roche Diagnostics Recognizes Sentara Consolidated Laboratories As Roche Molecular Center Of Excellence

Institution joins strategic network designed to help accelerate advancement of new methods in molecular diagnostics, anatomic pathology and sequencing

Genentech To Present New Data At AAN Reinforcing Efficacy And Safety Of Newly FDA Approved OCREVUS (Ocrelizumab) In Two Types Of Multiple Sclerosis

Genentech To Present New Data At AAN Reinforcing Efficacy And Safety Of Newly FDA Approved OCREVUS (Ocrelizumab) In Two Types Of Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS™ (ocrelizumab) in people with relapsing forms of multiple sclerosis (RMS) and primary progressive MS (PPMS)...

FDA Grants Genentech's TECENTRIQ (Atezolizumab) Accelerated Approval As Initial Treatment For Certain People With Advanced Bladder Cancer

FDA Grants Genentech's TECENTRIQ (Atezolizumab) Accelerated Approval As Initial Treatment For Certain People With Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Genentech's Lucentis (Ranibizumab Injection) For Diabetic Retinopathy, The Leading Cause Of Blindness Among Working Age Adults In The United States

FDA Approves Genentech's Lucentis (Ranibizumab Injection) For Diabetic Retinopathy, The Leading Cause Of Blindness Among Working Age Adults In The United States

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech Announces Positive Interim Results For Emicizumab In Phase III Study Of Children With Hemophilia A

Genentech Announces Positive Interim Results For Emicizumab In Phase III Study Of Children With Hemophilia A

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A...

Roche Launches New Global Certified Provider Program For Target Enrichment In Genomic Sequencing

Roche Launches New Global Certified Provider Program For Target Enrichment In Genomic Sequencing

-- Program helps meet customers' needs for both basic and clinical research applications

Phase III Study Shows Genentech's Alecensa® Was Superior To Crizotinib In A Specific Type Of Lung Cancer

Phase III Study Shows Genentech's Alecensa® Was Superior To Crizotinib In A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the global, randomized Phase III ALEX study met its primary endpoint and showed that Alecensa ® (alectinib) as an initial...

FDA Advisory Committee Unanimously Recommends Approval Of Genentech's Subcutaneous Rituximab For Certain Blood Cancers

FDA Advisory Committee Unanimously Recommends Approval Of Genentech's Subcutaneous Rituximab For Certain Blood Cancers

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Genentech's OCREVUS™ (Ocrelizumab) For Relapsing And Primary Progressive Forms Of Multiple Sclerosis

FDA Approves Genentech's OCREVUS™ (Ocrelizumab) For Relapsing And Primary Progressive Forms Of Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Grants Breakthrough Therapy Designation For Rituxan® (Rituximab) In Pemphigus Vulgaris

FDA Grants Breakthrough Therapy Designation For Rituxan® (Rituximab) In Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Mylan Settles With Genentech Over Patents for Breast Cancer Drug

Mylan Settles With Genentech Over Patents for Breast Cancer Drug

The settlement provides Mylan with global licenses for its trastuzumab product.

Roche Diagnostics Recognizes Poplar Healthcare As Roche Molecular Center Of Excellence

Roche Diagnostics Recognizes Poplar Healthcare As Roche Molecular Center Of Excellence

Strategic alliance network is designed to help accelerate advancement of new methods in molecular diagnostics testing and personalized healthcare

Phase III APHINITY Study Shows Genentech's Perjeta® Regimen Helped People With An Aggressive Type Of Early Breast Cancer Live Longer Without Their Disease Returning Compared To Herceptin® And Chemotherapy

Phase III APHINITY Study Shows Genentech's Perjeta® Regimen Helped People With An Aggressive Type Of Early Breast Cancer Live Longer Without Their Disease Returning Compared To Herceptin® And Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced positive results...

Rogers Corporation Reports Fourth Quarter 2016 And Full Year Results

Rogers Corporation Reports Fourth Quarter 2016 And Full Year Results

Rogers Corporation (NYSE:ROG) today announced financial results for the 2016 fourth quarter and full year.

Phase II Study Supports Potential For Genentech's Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) For People With Locally Advanced Or Metastatic Renal Cell Carcinoma

Phase II Study Supports Potential For Genentech's Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) For People With Locally Advanced Or Metastatic Renal Cell Carcinoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ ® (atezolizumab) plus Avastin ® (bevacizumab)...

Rogers Schedules Q4 & Full Year 2016 Earnings Call For Feb 21

Rogers Schedules Q4 & Full Year 2016 Earnings Call For Feb 21

Rogers Corporation (NYSE:ROG) plans to announce fourth quarter and full year 2016 results on February 20 after market close, which will be followed by a conference call on February 21 at 9 am ET.

News Out of Europe: Siemens Shares Hit Record High

News Out of Europe: Siemens Shares Hit Record High

Here is a round-up of the news from Europe.

FDA Grants Priority Review For Genentech's Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, A Form Of Vasculitis

FDA Grants Priority Review For Genentech's Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, A Form Of Vasculitis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Breakthrough Development For Americans With Suspected Heart Attack - Next Generation Troponin T Test From Roche Cleared By FDA

Breakthrough Development For Americans With Suspected Heart Attack - Next Generation Troponin T Test From Roche Cleared By FDA

New Troponin T 9-minute test offers greater sensitivity in the diagnosis of myocardial infarction